FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170311998> ?p ?o ?g. }

• W2170311998 endingPage "2487" @default.
• W2170311998 startingPage "2475" @default.
• W2170311998 abstract "Glioblastomas (GBMs) are very aggressive tumors that are resistant to conventional chemo- and radiotherapy. New molecular therapeutic strategies are required to effectively eliminate the subpopulation of GBM tumor-initiating cells that are responsible for relapse. Since EGFR is altered in 50% of GBMs, it represents one of the most promising targets; however, EGFR kinase inhibitors have produced poor results in clinical assays, with no clear explanation for the observed resistance. We uncovered a fundamental role for the dual-specificity tyrosine phosphorylation-regulated kinase, DYRK1A, in regulating EGFR in GBMs. We found that DYRK1A was highly expressed in these tumors and that its expression was correlated with that of EGFR. Moreover, DYRK1A inhibition promoted EGFR degradation in primary GBM cell lines and neural progenitor cells, sharply reducing the self-renewal capacity of normal and tumorigenic cells. Most importantly, our data suggest that a subset of GBMs depends on high surface EGFR levels, as DYRK1A inhibition compromised their survival and produced a profound decrease in tumor burden. We propose that the recovery of EGFR stability is a key oncogenic event in a large proportion of gliomas and that pharmacological inhibition of DYRK1A could represent a promising therapeutic intervention for EGFR-dependent GBMs." @default.
• W2170311998 created "2016-06-24" @default.
• W2170311998 creator A5020923109 @default.
• W2170311998 creator A5022179217 @default.
• W2170311998 creator A5031101472 @default.
• W2170311998 creator A5065478689 @default.
• W2170311998 creator A5066746973 @default.
• W2170311998 creator A5073260065 @default.
• W2170311998 creator A5076482262 @default.
• W2170311998 creator A5080323920 @default.
• W2170311998 creator A5081536279 @default.
• W2170311998 creator A5084077698 @default.
• W2170311998 creator A5084289915 @default.
• W2170311998 date "2013-05-01" @default.
• W2170311998 modified "2023-10-10" @default.
• W2170311998 title "Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth" @default.
• W2170311998 cites W1504060840 @default.
• W2170311998 cites W1608240838 @default.
• W2170311998 cites W1963558982 @default.
• W2170311998 cites W1966010049 @default.
• W2170311998 cites W1968961303 @default.
• W2170311998 cites W1975306522 @default.
• W2170311998 cites W1981895671 @default.
• W2170311998 cites W1987039497 @default.
• W2170311998 cites W1987413233 @default.
• W2170311998 cites W2001544973 @default.
• W2170311998 cites W2006575609 @default.
• W2170311998 cites W2011766094 @default.
• W2170311998 cites W2011845911 @default.
• W2170311998 cites W2018607339 @default.
• W2170311998 cites W2018671779 @default.
• W2170311998 cites W2020887748 @default.
• W2170311998 cites W2022164329 @default.
• W2170311998 cites W2026263665 @default.
• W2170311998 cites W2027520723 @default.
• W2170311998 cites W2028119906 @default.
• W2170311998 cites W2028803495 @default.
• W2170311998 cites W2029470215 @default.
• W2170311998 cites W2036384121 @default.
• W2170311998 cites W2038657036 @default.
• W2170311998 cites W2041532272 @default.
• W2170311998 cites W2045951959 @default.
• W2170311998 cites W2046822015 @default.
• W2170311998 cites W2051988683 @default.
• W2170311998 cites W2053439872 @default.
• W2170311998 cites W2054547257 @default.
• W2170311998 cites W2059335700 @default.
• W2170311998 cites W2060551076 @default.
• W2170311998 cites W2067845233 @default.
• W2170311998 cites W2070705072 @default.
• W2170311998 cites W2070799929 @default.
• W2170311998 cites W2072413539 @default.
• W2170311998 cites W2072685915 @default.
• W2170311998 cites W2079563164 @default.
• W2170311998 cites W2086216067 @default.
• W2170311998 cites W2093780592 @default.
• W2170311998 cites W2094882473 @default.
• W2170311998 cites W2096287682 @default.
• W2170311998 cites W2096992832 @default.
• W2170311998 cites W2099023875 @default.
• W2170311998 cites W2103997800 @default.
• W2170311998 cites W2104743043 @default.
• W2170311998 cites W2105279254 @default.
• W2170311998 cites W2107591555 @default.
• W2170311998 cites W2112703519 @default.
• W2170311998 cites W2115607198 @default.
• W2170311998 cites W2124078079 @default.
• W2170311998 cites W2133037949 @default.
• W2170311998 cites W2139268921 @default.
• W2170311998 cites W2146878112 @default.
• W2170311998 cites W2147328758 @default.
• W2170311998 cites W2147673571 @default.
• W2170311998 cites W2154391976 @default.
• W2170311998 cites W2168175722 @default.
• W2170311998 cites W2169290377 @default.
• W2170311998 doi "https://doi.org/10.1172/jci63623" @default.
• W2170311998 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3668845" @default.
• W2170311998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23635774" @default.
• W2170311998 hasPublicationYear "2013" @default.
• W2170311998 type Work @default.
• W2170311998 sameAs 2170311998 @default.
• W2170311998 citedByCount "104" @default.
• W2170311998 countsByYear W21703119982014 @default.
• W2170311998 countsByYear W21703119982015 @default.
• W2170311998 countsByYear W21703119982016 @default.
• W2170311998 countsByYear W21703119982017 @default.
• W2170311998 countsByYear W21703119982018 @default.
• W2170311998 countsByYear W21703119982019 @default.
• W2170311998 countsByYear W21703119982020 @default.
• W2170311998 countsByYear W21703119982021 @default.
• W2170311998 countsByYear W21703119982022 @default.
• W2170311998 countsByYear W21703119982023 @default.
• W2170311998 crossrefType "journal-article" @default.
• W2170311998 hasAuthorship W2170311998A5020923109 @default.
• W2170311998 hasAuthorship W2170311998A5022179217 @default.
• W2170311998 hasAuthorship W2170311998A5031101472 @default.
• W2170311998 hasAuthorship W2170311998A5065478689 @default.
• W2170311998 hasAuthorship W2170311998A5066746973 @default.

• next